Dovato, a combination medication for HIV-1 infection, received its initial FDA approval on April 5, 2019 [1].
When is Dovato's Patent Exclusivity Expected to End?
The patent exclusivity for Dovato is influenced by several factors, including the patents on its active ingredients (dolutegravir and lamivudine) and the specific formulation. DrugPatentWatch.com tracks these patents, providing detailed information on their expiry dates and any associated exclusivities [2]. Generally, innovator drug patents can last up to 20 years from the filing date, but various extensions and market exclusivities can alter the effective market protection period.
What are the Key Components of Dovato?
Dovato is a single-tablet regimen combining two antiretroviral drugs: dolutegravir and lamivudine [1]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) [3]. This dual-action approach targets HIV replication through different mechanisms.
Who Manufactures Dovato?
Dovato is manufactured by ViiV Healthcare [1]. ViiV Healthcare is a global specialist HIV company established in 2009 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi joining later [4].
How Does Dovato Compare to Other HIV Treatments?
Dovato offers a two-drug regimen, which is a departure from some traditional three-drug regimens. This approach aims to reduce drug exposure while maintaining viral suppression. It is indicated for the treatment of HIV-1 infection in patients without a known history of antiviral treatment failure and without known resistance to the individual components of Dovato [1]. Clinical trials have demonstrated its efficacy in achieving and maintaining viral suppression, comparable to some three-drug regimens [5].
Can Biosimilars Be Developed for Dovato?
The development of biosimilars for complex biological drugs can be lengthy. However, for small-molecule drugs like those in Dovato, the pathway is typically for generic versions rather than biosimilars. Generic versions can be developed and approved once the relevant patents and exclusivities expire, potentially leading to lower-cost treatment options [2].
What is the Mechanism of Action for Dovato?
Dolutegravir works by inhibiting the HIV integrase enzyme, a crucial protein for viral replication. It prevents the integration of viral DNA into the host cell's DNA. Lamivudine, a nucleoside analog, is phosphorylated intracellularly and then competes with natural substrates for incorporation into viral DNA by HIV reverse transcriptase. This incorporation terminates the growing DNA chain, halting viral replication [3].
What are the Potential Side Effects of Dovato?
Common side effects reported with Dovato include headache, diarrhea, nausea, insomnia, and fatigue [1]. Serious side effects are rare but can include hypersensitivity reactions, lactic acidosis, and hepatotoxicity [6]. Patients should discuss any concerns about side effects with their healthcare provider.
What is the Clinical Data Supporting Dovato's Approval?
Dovato's approval was based on clinical trial data, including the pivotal Phase III GEMINI 1 & 2 studies. These studies showed that Dovato maintained viral suppression (HIV-1 RNA <50 copies/mL) in a similar percentage of participants compared to a three-drug regimen, and participants on Dovato experienced fewer drug-related adverse events [5].
---
Sources:
[1] FDA Approval Letter for Dovato: https://www.accessdata.fda.gov/drugsatfdadocs/appletter/2019/211776Orig1s000,211777Orig1s000.pdf
[2] DrugPatentWatch.com: https://www.drugpatentwatch.com/
[3] Dovato Prescribing Information: https://www.viivhealthcare.com/-/media/ViiV-Healthcare/Products/US/Dovato/DovatoPrescribing_Information.pdf
[4] ViiV Healthcare About Us: https://www.viivhealthcare.com/en-us/about-viiiv-healthcare/
[5] ViiV Healthcare Press Release on Dovato Approval: https://www.viivhealthcare.com/en-us/press-releases/2019/may/viiv-healthcare-announces-us-approval-of-dovato-dolutegravir-lamivudine-tablets/
[6] HIV.gov Dovato Information: https://www.hiv.gov/hiv-basics/hiv-treatment/types-of-hiv-medication/dovato